APLLTD817.00

Alembic Pharmaceuticals Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersAJANTPHARMIPCALABTORNTPHARMALIVUSAKUMSAGARWALEYEADVENZYMESAARTIPHARMMcap ₹16,058 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations6,228.66,672.17,344.97,784.0
Other Income28.342.654.462.8
Total Income6,256.96,714.67,399.37,846.8
Expenses
+ Cost of Materials Consumed1,403.01,672.21,747.41,833.4
+ Purchases of Stock-in-Trade454.9411.0508.9520.2
+ Changes in Inventories-142.8-289.8-271.8-156.5
+ Employee Benefit Expense1,446.31,562.31,731.91,783.1
+ Finance Costs56.278.893.697.7
+ Depreciation & Amortisation272.7278.6318.6342.5
+ Other Expenses2,133.92,308.22,510.12,634.8
Total Expenses5,624.16,021.26,638.67,055.2
EBITDA933.41,008.21,118.51,169.0
EBIT660.7729.7799.9826.5
Profit
PBT before Exceptional Items632.8693.4760.7791.6
+ Exceptional Items0.012.9-67.0-67.0
Pretax Income632.8706.3693.7724.6
+ Current Tax62.1122.2127.6149.7
+ Deferred Tax-46.13.0-104.5-113.6
Tax Expense16.0125.223.136.1
+ Share of Associates & JVs-1.00.90.21.1
Net Income615.8582.0670.8689.6
+ Net Income — Continuing Ops616.8581.1670.6688.5
+ Other Comprehensive Income-10.85.524.926.4
Total Comprehensive Income605.0587.5695.7716.0
Net Income to Common615.8583.4674.8
Minority Interest0.0-1.43.9-1.6
Per Share
Basic EPS31.3329.6834.3335.27
Diluted EPS31.3329.6834.3335.27
Other Comprehensive Income — detail
+ Other Comprehensive Income5.524.926.4
+ Items NOT to be Reclassified to P&L-15.6-1.9-7.0-7.0
+ Tax on Items NOT to be Reclassified-1.0-0.8-0.9-1.0
+ Tax on Items NOT to be Reclassified — alt tag-1.0
+ Items to be Reclassified to P&L3.86.630.932.9
+ Tax on Items to be Reclassified0.00.00.5
Comprehensive Income — Owners of Parent605.0589.04.4504.3
Comprehensive Income — Non-controlling Interests0.0-1.4700.1211.7
Per Share — as-filed variants
Basic EPS — Continuing Operations31.3329.6834.3335.27
Diluted EPS — Continuing Operations31.3329.6834.3335.27
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit4,513.54,878.75,360.55,586.8
Gross Margin %72.4673.1272.9871.77
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)632.8693.4760.7791.6
− Exceptional Items (reconciliation)0.012.9-67.0-67.0
Net Income Adj (tax-effected)615.8571.4735.6753.2
EPS Adj31.3329.1437.6438.53
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value2.002.002.002.00
Filed Debt Equity0.000.000.000.00
Filed Dscr0.100.070.08
Filed Iscr0.100.080.09
Paid Up Equity Capital39.339.339.339.3
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.